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Introduction
In Europe rare diseases (RDs) are defined as 
"diseases with a prevalence in the European Union (EU) 
population of less than 5 per 10,000". This definition 
includes a large group of more than 6,000 diseases, 
90% of which are genetically determined and which 
potentially involve all organs1. RDs are therefore a 
very heterogeneous group as far as both clinical and 
epidemiological aspects are concerned. 
There are in fact RDs with less severe clinical 
manifestations and others with important ones which 
can compromise the quality of life and the life 
expectancy. Furthermore, some RDs have a prevalence 
approaching to the 5 per 10,000 limit and therefore 
affect a significant number of patients. Indeed, from 
the June 2005 to the December 2013 the Piedmont and 
Aosta Valley interregional register for RDs collected 
21,062, with an estimated overall prevalence of RD of 
45 patients on 10,000 inhabitants. Moreover half of the 
patients registered are affected by less than 20 diseases 
or groups of diseases (Table I) that represent the most 
important burden of care for the regional healthcare 
systems. On the other hand there are several with a 
much lower prevalence affecting a very small number 
of patients2.
These latter often lack of timely and correct 
diagnosis and adequate treatment. Moreover, the 
world-wide orphan drug policies are associated with 
unacceptably high costs of newly developed drugs and 
inaccessibility of previously available drugs which 
become unavailable over time because of limited 
production by pharmaceutical industries3.
Finally, despite the low prevalence of each disorder, 
the number of rare disease is fairly high. The European 
Commission reports that RDs affect a total of 6-8% of 
the population.
Due to all these problems, and to the fact that RDs are 
often chronic and invalidating or cause early mortality, 
they represent a significant public health matter of 
concern in many countries.
The Italian regulatory framework on RD
In Europe the problem of RDs was addressed for the 
first time by The Program of Community Action on rare 
diseases 1999-20034.
Italy was one of the first European countries to 
develop specific regulations regarding RDs5. Since 1998, 
the three year National Health Plans has been issued, 
intended as national-wide instructions. This document 
indicated RD as a priority for National Health Service 
(NHS). Moreover, in 2001, the Ministry of Health 
Table I   - Distribution of diseases covering 50% of reported 
diseases in the Piedmont and Aosta Valley Rare 
Diseases Registry.
Rare disease or group n. of patients % Cumulative %
Hereditary coagulation 
disorders
1,245 5.9% 5.9%
Lateral amyotrophic sclerosis 997 4.7% 10.6%
Hereditary anaemias 981 4.7% 15.3%
Progressive systemic 
sclerosis
888 4.2% 19.5%
Congenital metabolic iron 
disorders
745 3.5% 23.1%
Neurofibromatosis 607 2.9% 25.9%
Undifferentiated connective 
tissue disease
548 2.6% 28.5%
Sarcoidosis 487 2.3% 30.9%
Chronic idiopathic 
thrombocytopenic purpura
474 2.3% 33.1%
Antiphospolipids syndrome 451 2.1% 35.2%
Keratoconus 419 2.0% 37.2%
Idiopathic pulmonary 
fibrosis
399 1.9% 39.1%
Genetic arrhytmias 359 1.7% 40.8%
Down syndrome 358 1.7% 42.5%
Disorders of aminoacids 
metabolism and transport
356 1.7% 44.2%
Arnold-Chiari syndrome 337 1.6% 45.8%
Muscular dystrophies 332 1.6% 47.4%
Lichen sclerosus et 
atrophicus
289 1.4% 48.8%
Bullous pemhigoid 271 1.3% 50.1%
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comprehensively addressed the issue of RDs with a 
specific Decree (DM 279/2001)6. 
DM 279/2001 established the national network for 
RDs and cost exemptions for related health service 
provisions for a consistent cohort of RDs5. DM 279/2001 
also established a National Registry of RDs to be kept 
at the National Institute of Health7. A few months after 
the publication of DM 279/2001, a Constitutional 
Law (Constitutional Law 3/2001) reformed Title V of 
the Italian Constitution. Several decisions on health, 
including RDs, were consequently delegated to the 
regional administrations. As a result the development of 
networks for RDs was quite different among the various 
Italian Regions.
Prior to DM 279/2001, other national laws had dealt 
with specific RDs, such as cystic fibrosis and hereditary 
haemorrhagic diseases. For instance, as addressed in 
other papers in this issue, a network of reference centres 
for haemophilia and related disorders was already 
operating before 2001. 
The inclusion of these previously existing network 
for specific RDs was one of the problem faced by 
regional administrations in implementing DM 279/2001.
The regional RD networks: examples from the 
current experiences
The network of RDs was implemented following 
different organisation systems in various Italian regions.
In some of the smaller regions with a small 
population, such as Marche region, one or two reference 
centres paediatric and adult patients were established8.
In other regions, such as Veneto, reference centres 
for homogeneous nosological groups of diseases were 
set up. Moreover, these regions have created a network 
for local care in order to provide a day to day patients 
take in charge9.
A similar model was applied by the Tuscany region 
where a diagnostic network made up of reference centres 
and a care network interact with each other to manage 
the patient's healthcare needs10. 
Contrarily, the Lombardy Region applied a model 
based on establishing reference centres on which insist 
all the aspects of the diagnosis and care of the patient11.
A final model is the "hub and spoke model" which is 
implemented, for example, by Emilia Romagna. This model 
bases on concentrating the more complex cases in a limited 
number of centres (hubs). The clinical activity of the hub is 
highly integrated through functional connections with that 
of the peripheral health centres (spokes)12.
All the above models are based on establishing 
reference centres which are entrusted for the diagnosis 
of the disease and to supply the appropriate therapeutic 
prescription. In most cases the reference centres were 
established considering the number of treated patients 
and the scientific relevance of each centre. In some 
regions, such as in Lombardy, the reference centres are 
subject to periodic re-evaluation by a local coordinating 
Centre which evaluate all the above mentioned 
parameters.
Some regions have made inter-regional agreements. 
Therefore there are two formally recognized inter-
regional areas. The first one is made up of Piedmont 
and Aosta Valley. The second includes Veneto, the 
Autonomous Provinces of Trento and Bolzano, Friuli-
Venezia Giulia, Emilia-Romagna, Liguria, Puglia 
and Campania13,14. The regions involved in the two 
inter-regional networks share the same policy for the 
accreditation of reference centres, the information 
system for the management of the Registry of RDs, 
treatment protocols, and standards of care.
Finally, in 2006, all the Italian Regions and 
Autonomous Provinces joined in an inter-regional 
network for RDs with the purpose of a joined approach 
to common issues such as home administration of drugs 
for metabolic diseases and telemedicine.
The Piedmont and Aosta Valley network for 
RDs decentralised model
The Piedmont and Aosta Valley Inter-regional 
Network for RDs was developed in 2008. It is the result 
of the union between two previously separate systems, 
i.e., the Piedmont regional network for RDs, founded 
in 2004, and the system for RDs in the Aosta Valley 
region14,15. It is a decentralised organisational model 
based on the active involvement of all the professionals 
operating in the public health system of the two regions.
The Piedmont Network for RDs was created to 
guarantee equal opportunities of assistance throughout 
the Region, develop diagnostic and treatment protocols 
to be shared among physicians, provide information 
on regional health organization and legislation to care-
givers and patients' associations. It has also be created 
to collect data for epidemiological studies through the 
Regional Registry, allowing to identify both critical 
problems (including delays in diagnosis and care) and 
areas of possible investment of resources.
The Inter-Regional network for RDs was designed 
to develop a model of healthcare assistance that would 
guarantee the quality of diagnosis (including genetic 
analysis) in centres with proven expertise. More 
importantly, it aims to offer appropriate healthcare to 
patients as close as possible to their place of living. 
Thus, the Piedmont and Aosta Valley model of 
decentralised network for RDs is unique among the 
Italian experiences. Unlike most networks in other 
Italian regions, the Piedmont and Aosta Valley network 
involves all the healthcare facilities within the regions, 
thus giving all the specialists the opportunity to be 
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Piedmont and Aosta Valley network of rare diseases
Table II - Multidisciplinary working groups (so-called 
Consortia) at December 31, 2013. In bold are 
indicated the implemented clinical pathways.
Adrenogenital Syndromes
Amyloidosis
Anti-phospholipid Syndrome
Arnold Chiari Syndrome, Syringomyelia
Autoimmune peripheral neuropathies
Autoimmune Polyendocrinopathies
Bladder Pain Syndrome
Congenital Osteodystrophy
Hereditary coagulation Disorders
Hereditary retinal dystrophy
Klinefelter Syndrome
Neurofibromatosis
Lysosomal Storage Diseases
Porphyrias
Prader-Willi Syndrome
Precocious Puberty
Primary Lymphedema
Primary Pulmonary Hypertension
Systemic Sclerosis
Transition from childhood to adulthood
Undifferentiated Connective Tissue Disease
Uveitis
involved in treating patients with RDs. 
A network as widespread as that of Piedmont and 
Aosta Valley requires a Coordinating Centre and a 
monitoring system to evaluate the appropriateness of 
diagnoses and therapy. The Coordinating Centre was 
established in 2004 and, since 2005, it has been supported 
by a regional technical board15,16. The coordination of 
clinical activities for RDs throughout the two regions 
is guaranteed by Working Groups for RDs operating 
in all heath institutions of the public regional systems 
that act in collaboration with the Coordinating Centre. 
The supply of drugs for treatment of patients suffering 
from RDs is ensured by a wide network of hospital 
pharmacies. These provide all the needed medicinal 
products including drugs not currently available nation-
wide or still under investigation in selected cases, and 
off-label agents. In addition, they also produce galenic 
preparations which are essential for the treatment of 
specific RD. The network of collaboration for the 
productions of galenics among hospital pharmacies is, 
to date, unique in Italy17.
Another peculiarity of the network of RDs in Piedmont 
and Aosta Valley is the presence of multidisciplinary 
working groups, called Consortia, dedicated to specific 
RDs or to RDs with similar therapeutic or diagnostic 
problems. They operate throughout the two Regions 
and are composed of volunteer clinicians, other health 
professionals, and patient's associations. Consortia main 
goal is the development of shared protocols and clinical 
pathways18,19. The Consortia deal with the most prevalent 
RDs, or with the ones that are characterised by specific 
issues such as the cost of treatment or the lack of reliable 
data regarding treatment effectiveness and efficacy.
Twenty two Consortia were active at the end of 
2013. Fourteen disease-specific or disease group-
specific clinical pathways have been implemented to 
date (Table II). 
In addition to developing the clinical pathways, the 
Consortia also identify, if needed, Centres of Expertise. 
A Centre of Expertise must have proven diagnostic 
and therapeutic experience as well as availability of 
appropriate support structures and complementary 
services, such as laboratory and imaging facilities, 
emergency department availability, etc. The main aims 
of the centres of expertise are supporting the local 
health authorities in the care of patients, and providing 
specialised training to the health professionals. To 
date, Centres of Expertise have been established for 
amyotrophic lateral sclerosis, for syringomyelia, and 
Arnold-Chiari syndrome.
Lastly, an important activity of the Consortia is the 
production of clinical and epidemiological studies on 
RDs19-24.
The Piedmont and Aosta Valley network for rare 
diseases is also involved in international collaborations, such 
as the network International Conference for Rare Diseases 
and Orphan Drugs, Europlan initiatives promoted by the 
National Institute of Health, by the European Community, 
and by Eurordis, and in the rare diseases coding promoted 
by World Health Organization and by Orphanet. 
Conclusion
The network of RDs in Piedmont and Aosta Valley is 
a unique experience in the Italian scenario. An analysis 
of 10 years of activity allows us to give a largely positive 
assessment. This widespread network has improved the 
clinicians' knowledge of the specific RD. 
Moreover, the clinical activities of the Consortia 
and of the Network of Hospital Pharmacies allowed to 
provide appropriate cares to patients and to limit both 
the costs and the therapeutic healthcare mobility toward 
other regions. 
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